Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
• To capture the treatment patterns and clinical characteristics of patients with ER/PR
 positive, HER2-negative MBC in Greece
-  To capture the treatment patterns and clinical characteristics of patients with ER/PR
 positive, HER2-negative MBC in Greece

 -  To evaluate the outcome of patients per treatment line (objective response, progression
 free survival, time to disease progression per line of therapy), overall survival

 -  To record adverse events per line of therapy

 -  To recording of the causes of treatment discontinuation per line of therapy
Inclusion Criteria:

 -  Women with histological confirmed ER/PR positive, HER2-negative MBC

 -  Age >18 years old

 -  Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC

 -  Adequate hematologic, renal and hepatic function

 -  Signed informed consent (ICF)

 Exclusion Criteria:

 -  Active malignancy other than MBC

 -  Active infection